<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937544</url>
  </required_header>
  <id_info>
    <org_study_id>JEP-2019-003</org_study_id>
    <secondary_id>FF-2019-138</secondary_id>
    <nct_id>NCT03937544</nct_id>
  </id_info>
  <brief_title>Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL</brief_title>
  <official_title>A Phase II/III Prospective, Open Label Study to Evaluate Safety and Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed/ Refractory B-Acute Lymphoblastic Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University of Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gaia Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National University of Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is Phase II / III, Prospective, single arm, Open Label Study to Evaluate Safety and
      Efficacy of Intravenous Autologous CD19 CAR-T Cells for Relapsed / Refractory B-Acute
      Lymphoblastic Leukaemia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Anticipated">March 18, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Participants will be followed for the duration of the treatment, with an expected average of 3 months.</time_frame>
    <description>Overall Response Rate (ORR) defined as Complete Response (CR) and CR with incomplete blood recovery (CRi) according to WHO criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response (CR)</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration of response defined from the time when criteria for response (CR or CRi) are met to the first documentation of relapse or progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CR with incomplete blood recovery (CRi).</measure>
    <time_frame>12 Months</time_frame>
    <description>Duration of response defined from the time when criteria for response (CR or CRi) are met to the first documentation of relapse or progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 Months, 24 Months</time_frame>
    <description>Overall Survival (OS) defined as the time from treatment to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>12 Months, 24 Months</time_frame>
    <description>Progression Free Survival (PFS) defined as the time from treatment to first documentation of objective leukemic progression (date of leukaemia assessment documenting progressive disease) or to death due to any cause. Progression is assessed by BM biopsy or CSF analysis according to NCCN criteria. It is assessed at Day 30 and monthly thereafter, or earlier if clinically indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TTNT)</measure>
    <time_frame>12 Months, 24 Months</time_frame>
    <description>Time To Next Treatment (TTNT) defined as the end of study treatment until the institution of the next therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of participants with adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Relapsed B Acute Lymphoblastic Leukaemia</condition>
  <condition>Refractory B Acute Lymphoblastic Leukaemia</condition>
  <arm_group>
    <arm_group_label>CD19 CAR-T CELLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19 CAR-T CELLS</intervention_name>
    <description>CD19 CAR-T cells will be administered after completion of the chemotherapy.</description>
    <arm_group_label>CD19 CAR-T CELLS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Patients will receive lymphodepleting chemotherapies consisting Cyclophosphamide 250mg/m2/day IV(Day -5, Day -4, Day -3 ).</description>
    <arm_group_label>CD19 CAR-T CELLS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Patients will receive lymphodepleting chemotherapies consisting of Fludarabine 25mg/m2/day IV (Day -5, Day -4, Day -3 ).</description>
    <arm_group_label>CD19 CAR-T CELLS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsed/refractory B-ALL in accordance with World Health Organization
             (WHO) classification by virtue of BM morphology, flow cytometry, cytogenetics and
             molecular genetics

          -  Age between ≥13 to ≤ 65 years

          -  No detectable leukaemia in the CSF (CNS-1)

          -  CNS leukaemia without clinically evident neurological symptoms (CNS-2; with &lt;5 WBC per
             μL and cytology positive for blasts)

          -  Adequate organ function as defined by a creatinine clearance &gt; 50 ml/min, serum total
             bilirubin &lt; 5 times the normal value, left ventricular ejection fraction &gt; 40%

          -  ECOG performance status ≤ 2

          -  Life expectancy &gt; 3 months

          -  Post allogeneic HSCT must be ≥ Day +100 with no evidence of active GVHD and not
             receiving immunosuppression

          -  Female patients of child bearing age must have negative pregnancy test and is on
             highly effective contraception methods

          -  Male patients must use highly effective contraception methods

        Exclusion Criteria:

          -  Patients with CNS-3 leukaemia.

          -  Active cancer (other than B-ALL).

          -  Evidence of severe lung, heart (NYHA class III/IV, arrhythmia, AV block, uncontrolled
             hypertension), liver, or renal failure or severe neurologic disorder.

          -  Presence of active autoimmune disease or atopic allergy.

          -  HIV serology positivity.

          -  Active Hepatitis B or C infection as evidenced by quantitative viral PCR assay.

          -  Uncontrolled sepsis

          -  Pregnant / nursing female.

          -  Ongoing prednisolone &gt; 1mg/kg daily or equivalent.

          -  Chemotherapy immunotherapy in the recent 4 weeks such as allogeneic cellular therapy
             weeks, anti-GVHD therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>S Fadilah Abdul Wahid, MD, DrIntMed, PhD</last_name>
    <phone>+60391456450</phone>
    <email>sfadilah@ppukm.ukm.edu.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>UKM Medical Centre</name>
      <address>
        <city>Bandar Tun Razak</city>
        <state>Kuala Lumpur</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S Fadilah Abdul Wahid, MD, DrIntMed, PhD</last_name>
      <phone>+60391456450</phone>
      <email>sfadilah@ppukm.ukm.edu.my</email>
    </contact>
    <contact_backup>
      <last_name>Wan Fariza Wan Jamaludin, MD,DrIntMed</last_name>
      <phone>+60391457709</phone>
      <email>wanfariza@ppukm.ukm.edu.my</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National University of Malaysia</investigator_affiliation>
    <investigator_full_name>Prof. Dr S Fadilah Abdul Wahid</investigator_full_name>
    <investigator_title>Head of Pusat Terapi Sel / Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

